In our first six years, we have awarded over
$2.1 Million for Research Studies!
We awarded the first of three $1,000,000 study grants to Dr. Tomoo Iwakuma for a three-year study for Osteosarcoma titled “Capitalizing on p/53 loss/mutations in osteosarcoma through novel compounds”.
The goal for this proposal is to develop small-molecule drugs that specifically suppress growth of OS cells that lack the p53 activity and characterize these drugs in preclinical proof-of-concept studies.
We funded a two-year, $200,000 study to Dr. Andrew Godwin and Dr. Glenson Samuel at KU Medical Center for Ewings Sarcoma research. The study is “Exosome miRNAs as biomarkers and targets for chemoresistance in Ewing Sarcoma”.
We also funded a two-year, $300,000 study to Dr. Shrikant Anant from KU Medical Center and Dr. Kathleen Chastain from Children’s Mercy Hospital for “Sarcoma in a Dish: a novel approach for precision medicine”. This study seeks to find answers for Rhabdomyosarcoma cancers in children.
We funded a third study which was a one-year $100,000 study to Dr. Yael Mosse, titled “Immunotherapeutic Strategies to Target ALK on the Cell Surface of High Risk Neuroblastoma”. This study addresses high risk neuroblastoma and is a precision medicine approach to treating this deadly disease.
Two grants were awarded this year. One was to Dr. Kathleen Chastain from Children’s Mercy Hospital in conjunction with Dr. Shrikant Anant at KU Medical Center for rhabdomyosarcoma research. The amount of that grant was $193,700.
The second grant totaling $100,000 was awarded to Dr. Andrew Godwin from KU Medical Center in conjunction with Dr. Kathleen Chastain of Children’s Mercy Hospital for work in the area of Ewings Sarcoma.
We awarded two grants in 2014. One was to Dr. Kathleen Neville at Children’s Mercy Hospital in conjunction with Dr. Giselle Sholler from Helen deVos Hospital in Grand Rapids, Michigan. This was a Phase One research trial with two targeted treatment drugs called DFMO and Velcade which are given to patients who have gone through neuroblastoma treatments in an attempt to keep them in remission as a high percentage of neuroblastoma patients relapse.
The second grant was awarded in 2014 was to Dr. Doug Myers from Children’s Mercy Hospital in partnership with Dr. Thomas Yankee at KU Medical Center. Their research focuses on all solid mass tumors and the grant title was Next generation chimeric antigen receptors for personalized anti-tumor therapy. Their work focuses on infusing donor cells from a relative that are “supercharged” into a childhood cancer patient. Those cells then target cancer cells to destroy them and teach the child’s own immune system to recognize the invading cancer cells and destroy them. This is the second phase of their work and the preliminary results from the first phase of their work were extremely promising.
Our first grant was awarded to Dr. Jason Shohet at Texas Children’s Hospital to find a specific stem cell that is believed to be an activator of neuroblastoma cancers. His work was designed to find that cell, learn what activates it, and then develop a treatment that would shut that cell activator down.